CSG Law Alert: Supreme Court Unanimously Clarifies Induced-Infringement Risk for Skinny-Label Generic Drug Manufacturers
On June 4, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. No. 24-889, the Supreme Court unanimously held for the generic drug manufacturer Hikma, reversing the lower Court’s denial of its Motion to Dismiss. The Supreme Court decided that the brand manufacturer Amarin failed to plausibly plead induced infringement under 35 U.S.C. §271(b) based on Hikma’s skinny label, related product materials, website statements, and press releases.
The Supreme Court emphasized that inducing infringement of a method of treatment patent requires plausible, affirmative steps to bring about the infringement, not merely statements or circumstances from which infringement could possibly occur. For generic manufacturers, this decision provides important support for lawful skinny-label strategies while reinforcing the importance of wording and context in all labeling, marketing, and public communications.
I. Background and the Court’s Holding
Hikma began marketing a generic version of Amarin’s brand name drug-Vascepa® (icosapent ethyl). Vascepa® was first approved by the Food and Drug Administration (FDA) for treatment of severe hypertriglyceridemia (the “SH indication”), and then later approved for a second, more common use: reducing cardiovascular risk in hypertriglyceridemia patients who already take statins (the “CV indication”).
In prior proceedings, Amarin’s patents for the SH indication were invalidated and the current litigation only involved the method of treatment patents for the CV indication. Hikma filed an abbreviated new drug application for generic icosapent ethyl, seeking approval of a “skinny label” that included the indication to treat only SH. Amarin sued Hikma for induced infringement of its CV method of treatment patents.
A claim for active inducement of infringement under §271(b) requires three elements:
- Direct infringement by a third party;
- Knowledge that the induced acts constitute patent infringement; and
- Active steps to encourage direct infringement.
At issue in this case was the third element, “active steps.” The Supreme Court has defined active steps as “purposeful, culpable expression and conduct,” and excludes “ordinary acts incident to product distribution,” which are insufficient to support liability.
The case came to the Supreme Court after the trial Court granted Hikma’s motion to dismiss and the Court of Appeals for the Federal Circuit reversed, finding that it was at least plausible “that a physician could read” the relevant statements found on the label and in marketing materials “as an instruction or encouragement to” infringe.
The Supreme Court found that the Federal Circuit’s decision “was error.” The Supreme Court focused on whether Amarin’s Complaint plausibly alleged that Hikma actively encouraged infringement and held that Amarin did not meet this pleading standard.
II. Key Takeaways for Generic Drug Manufacturers
- A well-executed skinny-label strategy remains a viable pathway to market entry where only some methods of treatment have patent coverage.
- Truthful statements that a product is therapeutically equivalent or a generic version of the branded drug are not, without more, enough to support an inducement claim.
- Generic manufacturers must use care not to take active steps facilitating inducement risk.
III. Practical Next Steps
Inducement cannot be based only on “vague” language “combined with speculation about how [others] may act,” but, potential issues remain that should be proactively avoided.
The following steps are prudent:
- Prior to submitting an ANDA application with a section viii statement, review proposed product materials and external communications/for language that could be interpreted as encouraging a patented use.
- After launch, continually evaluate website content, investor relations materials, and any other publicly facing documents for messaging that avoids active encouragement to treat the patented use.
- Ensure the generic drug’s website is maintained with clarifying language that your generic is indicated for fewer than all approved indications of the brand drug.
If you would like to discuss this case and its ramifications, please contact the authors of this alert or the Patent Group at CSG Law.